Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.17 USD | -0.63% | +0.63% | -17.45% |
Apr. 04 | Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug | MT |
Apr. 04 | Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 190M |
---|---|---|---|---|---|
Net income 2024 * | -68M | Net income 2025 * | -93M | EV / Sales 2024 * | - |
Net cash position 2024 * | 121M | Net cash position 2025 * | 258M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.6
x | P/E ratio 2025 * |
-2
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.87% |
Latest transcript on Acumen Pharmaceuticals, Inc.
1 day | -0.63% | ||
1 week | +0.63% | ||
Current month | -21.73% | ||
1 month | -15.47% | ||
3 months | -2.16% | ||
6 months | -1.55% | ||
Current year | -17.45% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Jim Doherty
PSD | President | 56 | Jan. 31 |
Matthew Zuga
DFI | Director of Finance/CFO | 58 | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Director/Board Member | 55 | 22-03-31 | |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 3.17 | -0.63% | 140,701 |
24-04-25 | 3.19 | +0.31% | 167,647 |
24-04-24 | 3.18 | +0.63% | 152,249 |
24-04-23 | 3.16 | +0.96% | 270,690 |
24-04-22 | 3.13 | -0.63% | 479,020 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.45% | 190M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ABOS Stock